at mineralys therapeutics we aim to redefine hypertension diagnosis, management and treatment. we are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.
Company profile
Ticker
MLYS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MLYS stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
12 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
S-3/A
Shelf registration (amended)
29 Mar 24
8-K
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
S-3
Shelf registration
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
Latest ownership filings
4
David Malcom Rodman
15 Apr 24
4
David Malcom Rodman
13 Mar 24
4
David Malcom Rodman
15 Feb 24
4
Adam Scott Levy
15 Feb 24
4
Jon Congleton
15 Feb 24
SC 13G
TCG Crossover GP II, LLC
15 Feb 24
4
SRINIVAS AKKARAJU
14 Feb 24
4
Change in insider ownership
14 Feb 24
4
Peter Kolchinsky
14 Feb 24
SC 13G
ADAMS STREET PARTNERS LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 86.30 mm | 86.30 mm | 86.30 mm | 86.30 mm | 86.30 mm | |
Cash burn (monthly) | 4.95 mm | 4.33 mm | 8.76 mm | 4.75 mm | 1.06 mm | |
Cash used (since last report) | 32.72 mm | 28.63 mm | 57.93 mm | 31.39 mm | 7.04 mm | |
Cash remaining | 53.58 mm | 57.67 mm | 28.37 mm | 54.91 mm | 79.26 mm | |
Runway (months of cash) | 10.8 | 13.3 | 3.2 | 11.6 | 74.4 |
Institutional ownership, Q2 2023
65.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 70 |
Opened positions | 12 |
Closed positions | 10 |
Increased positions | 31 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 425.89 bn |
Total shares | 32.57 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Samsara BioCapital | 4.52 mm | $81.39 mm |
Samsara BioCapital | 4.52 mm | $77.06 bn |
Ra Capital Management | 3.18 mm | $54.19 bn |
Andera Partners | 2.87 mm | $51.62 mm |
Adams Street Partners | 2.42 mm | $41.25 bn |
SR One Capital Management | 1.79 mm | $30.60 bn |
Rock Springs Capital Management | 1.17 mm | $19.91 bn |
Vanguard | 926.01 k | $15.79 bn |
RTW Investments | 922.10 k | $15.72 bn |
BLK Blackrock | 884.26 k | $15.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | David Malcom Rodman | Common Stock | Option exercise | Acquire M | No | No | 1.08 | 6,349 | 6.86 k | 66,997 |
12 Apr 24 | David Malcom Rodman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.08 | 6,349 | 6.86 k | 203,154 |
11 Apr 24 | David Malcom Rodman | Common Stock | Option exercise | Acquire M | No | No | 0.54 | 5,017 | 2.71 k | 60,648 |
11 Apr 24 | David Malcom Rodman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.54 | 5,017 | 2.71 k | 45,156 |
12 Mar 24 | David Malcom Rodman | Common Stock | Option exercise | Acquire M | No | No | 1.08 | 6,348 | 6.86 k | 55,631 |
12 Mar 24 | David Malcom Rodman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.08 | 6,348 | 6.86 k | 209,503 |
11 Mar 24 | David Malcom Rodman | Common Stock | Option exercise | Acquire M | No | No | 0.54 | 5,017 | 2.71 k | 49,283 |
11 Mar 24 | David Malcom Rodman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.54 | 5,017 | 2.71 k | 50,173 |
12 Feb 24 | Ra Capital Management | Common Stock | Grant | Acquire A | Yes | No | 13.5 | 1,672,508 | 22.58 mm | 2,983,755 |
12 Feb 24 | Ra Capital Management | Pre-Funded Warrants Common Stock | Grant | Acquire A | Yes | No | 13.499 | 549,755 | 7.42 mm | 549,755 |
News
Goldman Sachs Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $30
2 Apr 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Mineralys Therapeutics Earnings Preview
20 Mar 24
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
8 Feb 24
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
8 Feb 24